An increase in HRAS mutations was also reported (6.9% for UTUC; 2.8%, for BUC), with most of the HRAS-altered tumours arising from UTUC of the renal pelvis rather than from other anatomic sites. This evidence concerns the gene HRAS and renal pelvis/ureter urothelial carcinoma.